We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.38B
1-Year Est. Return 407.79%
This Fund
S&P 500
This Quarter Est. Return
+7.49%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$303M
AUM Growth
+$28.3M
Cap. Flow
+$37.5M
Cap. Flow %
12.35%
Top 10 Hldgs %
76.75%
Holding
21
New
1
Increased
7
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$15.3M
2
ZGNX
Zogenix, Inc.
ZGNX
+$8.2M
3
KROS icon
Keros Therapeutics
KROS
+$7.16M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$7.08M
5
ARGX icon
argenx
ARGX
+$6.08M

Top Sells

Rank Stock Value
1
TRIL
Trillium Therapeutics Inc.
TRIL
+$15.6M
2
ALLK
Allakos
ALLK
+$2.31M
3
AMRN
Amarin Corp
AMRN
+$41.4K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
1
DELISTED
Zogenix, Inc.
ZGNX
$40.7M 13.41%
2,502,259
+560,000
+29% +$8.2M
INSM icon
2
Insmed
INSM
$22.7B
$35.8M 11.8%
1,313,607
– –
ENTA icon
3
Enanta Pharmaceuticals
ENTA
$370M
$29M 9.55%
387,400
+70,448
+22% +$5.53M
ARGX icon
4
argenx
ARGX
$55.6B
$27.5M 9.08%
78,644
+20,000
+34% +$6.08M
GBT
5
DELISTED
Global Blood Therapeutics, Inc.
GBT
$21.7M 7.17%
743,000
+493,000
+197% +$15.3M
VRDN icon
6
Viridian Therapeutics
VRDN
$2.18B
$18.7M 6.15%
944,092
– –
NUVL
7
DELISTED
Nuvalent
NUVL
$17.4M 5.74%
914,614
– –
KROS icon
8
Keros Therapeutics
KROS
$202M
$17.1M 5.65%
292,833
+143,500
+96% +$7.16M
COGT icon
9
Cogent Biosciences
COGT
$6.91B
$13.4M 4.41%
1,558,975
– –
TIL icon
10
Instil Bio
TIL
$48.5M
$11.5M 3.8%
33,695
– –
ACAD icon
11
Acadia Pharmaceuticals
ACAD
$4.35B
$9.73M 3.21%
416,817
– –
TYRA icon
12
Tyra Biosciences
TYRA
$1.85B
$9.08M 2.99%
645,349
+146,309
+29% +$2.91M
PNT
13
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$8.51M 2.81%
1,519,382
+419,893
+38% +$3.15M
AMRN
14
Amarin Corp
AMRN
$290M
$8.42M 2.78%
124,912
-500
-0.4% -$41.4K
BHVN
15
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$7.67M 2.53%
+55,647
New +$7.08M
IOVA icon
16
Iovance Biotherapeutics
IOVA
$2.19B
$7.44M 2.45%
389,588
– –
AXSM icon
17
Axsome Therapeutics
AXSM
$12.3B
$7.09M 2.34%
187,598
– –
VRNA
18
DELISTED
Verona Pharma
VRNA
$6.23M 2.05%
926,602
– –
ATXS
19
DELISTED
Astria Therapeutics
ATXS
$4.91M 1.62%
911,736
– –
ALLK
20
DELISTED
Allakos
ALLK
$1.44M 0.48%
147,189
-28,173
-16% -$2.31M
TRIL
21
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-886,281
Closed -$15.6M

Similar funds

NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
VC
Vestor Capital Chicago, Illinois $1.38B AUM 39.2% 1-Year Est. Return
AO
Advisor OS Chicago, Illinois $1.38B AUM 16.6% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return

Fairmount Funds Management's Q4 2021 Portfolio in Review

As of Q4 2021, Fairmount Funds Management held 21 positions worth $303M, up 10% from $275M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Fairmount Funds Management deployed $37.5M of net new capital in Q4 2021, opening 1 new position and adding to 7 existing holdings. Its largest new stake was Biohaven Pharmaceutical Holding Company Ltd.: 55,647 shares worth $7.67M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 94% a quarter earlier.

On the sell side, the largest reduction was Allakos, an estimated $2.31M trimmed.

  • Fairmount Funds Management's largest Q4 2021 buy was Biohaven Pharmaceutical Holding Company Ltd.: 55,647 shares worth $7.67M.
  • Fairmount Funds Management added most to Global Blood Therapeutics, Inc. in Q4 2021, an estimated $15.3M increase.
  • Fairmount Funds Management's biggest Q4 2021 reduction was Allakos, cutting an estimated $2.31M.
  • Fairmount Funds Management fully exited Trillium Therapeutics Inc. in Q4 2021, selling an estimated $15.6M.
  • Fairmount Funds Management's ten largest holdings make up 77% of its $303M portfolio in Q4 2021.
  • Fairmount Funds Management opened 1 new position and closed 1 in Q4 2021.
  • Fairmount Funds Management's portfolio value rose 10% quarter-over-quarter to $303M.

Based on Fairmount Funds Management's 13F filing for Q4 2021, filed 14 Feb 2022.